GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Item 9 Labs Corp (OTCPK:INLB) » Definitions » Beneish M-Score

Item 9 Labs (Item 9 Labs) Beneish M-Score : -2.84 (As of Apr. 30, 2024)


View and export this data going back to 2011. Start your Free Trial

What is Item 9 Labs Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -2.84 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Item 9 Labs's Beneish M-Score or its related term are showing as below:

INLB' s Beneish M-Score Range Over the Past 10 Years
Min: -287.35   Med: -9.74   Max: 14.16
Current: -2.84

During the past 13 years, the highest Beneish M-Score of Item 9 Labs was 14.16. The lowest was -287.35. And the median was -9.74.


Item 9 Labs Beneish M-Score Historical Data

The historical data trend for Item 9 Labs's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Item 9 Labs Beneish M-Score Chart

Item 9 Labs Annual Data
Trend Sep13 Sep14 Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only - -1.57 -4.54 -0.10 -3.98

Item 9 Labs Quarterly Data
Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -4.60 -3.98 -4.11 -3.97 -2.84

Competitive Comparison of Item 9 Labs's Beneish M-Score

For the Drug Manufacturers - Specialty & Generic subindustry, Item 9 Labs's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Item 9 Labs's Beneish M-Score Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Item 9 Labs's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Item 9 Labs's Beneish M-Score falls into.



Item 9 Labs Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Item 9 Labs for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 1.9805+0.528 * 0.6708+0.404 * 1.0289+0.892 * 0.8256+0.115 * 1.1237
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 1.1726+4.679 * -0.161746-0.327 * 1.5222
=-2.84

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Jun23) TTM:Last Year (Jun22) TTM:
Total Receivables was $0.97 Mil.
Revenue was 5.022 + 5.663 + 5.004 + 4.001 = $19.69 Mil.
Gross Profit was 2.819 + 3.718 + 2.622 + 0.646 = $9.81 Mil.
Total Current Assets was $3.35 Mil.
Total Assets was $112.02 Mil.
Property, Plant and Equipment(Net PPE) was $24.97 Mil.
Depreciation, Depletion and Amortization(DDA) was $1.83 Mil.
Selling, General, & Admin. Expense(SGA) was $17.91 Mil.
Total Current Liabilities was $58.81 Mil.
Long-Term Debt & Capital Lease Obligation was $0.15 Mil.
Net Income was -5.911 + -3.417 + -3.258 + -18.449 = $-31.04 Mil.
Non Operating Income was -0.169 + 0 + 0.003 + -11.631 = $-11.80 Mil.
Cash Flow from Operations was 0.15 + 0.303 + -1.335 + -0.238 = $-1.12 Mil.
Total Receivables was $0.59 Mil.
Revenue was 4.931 + 6.638 + 6.186 + 6.094 = $23.85 Mil.
Gross Profit was 1.59 + 2.677 + 2.399 + 1.301 = $7.97 Mil.
Total Current Assets was $5.69 Mil.
Total Assets was $120.53 Mil.
Property, Plant and Equipment(Net PPE) was $27.31 Mil.
Depreciation, Depletion and Amortization(DDA) was $2.27 Mil.
Selling, General, & Admin. Expense(SGA) was $18.49 Mil.
Total Current Liabilities was $39.47 Mil.
Long-Term Debt & Capital Lease Obligation was $2.21 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(0.968 / 19.69) / (0.592 / 23.849)
=0.049162 / 0.024823
=1.9805

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(7.967 / 23.849) / (9.805 / 19.69)
=0.33406 / 0.497969
=0.6708

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (3.347 + 24.968) / 112.015) / (1 - (5.692 + 27.308) / 120.528)
=0.747221 / 0.726205
=1.0289

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=19.69 / 23.849
=0.8256

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(2.271 / (2.271 + 27.308)) / (1.831 / (1.831 + 24.968))
=0.076777 / 0.068323
=1.1237

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(17.905 / 19.69) / (18.494 / 23.849)
=0.909345 / 0.775462
=1.1726

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((0.145 + 58.813) / 112.015) / ((2.205 + 39.47) / 120.528)
=0.52634 / 0.34577
=1.5222

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-31.035 - -11.797 - -1.12) / 112.015
=-0.161746

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Item 9 Labs has a M-score of -2.84 suggests that the company is unlikely to be a manipulator.


Item 9 Labs Beneish M-Score Related Terms

Thank you for viewing the detailed overview of Item 9 Labs's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Item 9 Labs (Item 9 Labs) Business Description

Traded in Other Exchanges
N/A
Address
2111 E. Highland Avenue, Suite B375, Phoenix, AZ, USA, 85016
Item 9 Labs Corp is a vertically integrated cannabis operator and dispensary franchisor delivering premium products from its large-scale cultivation and production facilities in the United States. The Item 9 Labs brand specializes in products and user experience across several cannabis categories. The company also offers a dispensary franchise model through the national Unity Rd. retail brand. Easing barriers to entry, the franchise provides an opportunity for both new and existing dispensary owners to leverage the knowledge, resources, and ongoing support needed to thrive in their state compliantly and successfully. It also brings industry practices to markets nationwide through distinctive retail experience, cultivation capabilities, and product innovation.
Executives
Taylor Lawrence X. Iii director 2727 N 3RD STREET, SUITE 201, PHOENIX AZ 85004
Eric Kutscher director 2727 N 3RD STREET, SUITE 201, PHOENIX AZ 85004
Michael P Keskey director C/O ITEM 9 LABS, 2727 N. 3RD STREET, SUITE 201, PHOENIX AZ 85004
Douglas P Bowden director C/O ITEM 9 LABS 2727 N. 3RD STREET., SUITE 201, PHOENIX AZ 85004
Christopher Leland Wolven officer: Chief Operating Officer 5743 N 19TH ST, PHOENIX AZ 85016
Sara Gullickson director, officer: Chief Executive Officer 1709 BETHANY RD, PHOENIX AZ 85016
Andrew Douglas Bowden director 3621 N 39TH ST, PHOENIX AZ 85018
Robert E Mikkelsen officer: CFO, Secretary, Treasurer 2033 N OVERFIELD RD, CASA GRANDE AZ 85194
Patrick Sean Dugan 10 percent owner 2033 N OVERFIELD RD, CASA GRANDE AZ 85194
Andrew Poirier 10 percent owner 1946 E RANCHO DR, PHOENIX AZ 85016
Bryce Skalla director, officer: President 2033 N OVERFIELD RD, CASA GRANDE AZ 85194
Cohen Daniel E Md director, officer: President 10035 GRISTMILL RIDGE, EDEN PRAIRIE MN 55347
Hayjour Family Limited Partnership director, officer: President & CEO 10799 N 90TH STREET, SUITE 200, SCOTTSDALE AZ 85260
Jessica L Smith officer: CFO, Secretary, Treasurer 8399 E. INDIAN SCHOOL RD., SUITE 202, SCOTTSDALE AZ 85251
Lorrie Henderson officer: Chief Operating Officer 8399 E INDIAN SCHOOL RD, SUITE 202, SCOTTSDALE AZ 85251